Healios and Athersys Enter Into Regenerative Medicine Partnership for Treatment of Stroke Using MultiStem(R) Therapy
CLEVELAND and TOKYO, Jan. 08, 2016 – Healios K.K. (“Healios”) (Tokyo Stock Exchange:4593) and Athersys, Inc. (“Athersys”) (NASDAQ:ATHX) have announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy treatments, including MultiStem® for the treatment of ischemic stroke and potentially other indications, in Japan. The partnership involves MultiStem, a proprietary, patented off-the-shelf stem cell therapy being developed by Athersys, with an initial focus on treating ischemic stroke.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.